The rise of digital innovation presents an opportunity for Pharma to reimagine its core enterprises, revamp its R&D, and re-centre consumers and patients. But these possibilities will only become reality through deep, meaningful collaborations with healthcare’s wider ecosystem of SMEs, tech companies, and payers and providers, a priority which the COVID-19 pandemic pushed to the top of the agenda.

In this complimentary 40-minute session, leading Pharma executives from across Europe and the US discuss the most promising partnership strategies, rising opportunities for digital health in Pharma, and how innovators can position themselves to become a part of biopharma’s digital shift.

What will be covered?

  • In which areas and verticals are pharma leveraging partnerships to bringing treatments and interventions to market?
  • What are the key success factors for a pharma-innovator collaboration? Has COVID-19 caused pharma to fall back or double down on its commitment to digitisation?
  • Which verticals present the biggest opportunity for pharma to leverage innovation?

Rachel Sha, Head of Digital BD and Licensing, Sanofi
Anders Dyhr Toft, Corporate Vice President Commercial Innovation, Novo Nordisk
Lauren Li, Head of Digital Health, Ipsen
Joel Krikston
, Head of Strategic Innovation Alliance, Merck Global Health Innovation Group

Moderator: Rachel Ford Hutman, Founder and CEO, Ford Hutman Media

Written By